先端医療シリーズ31 腎臓病 診断と治療の最前線

出版社: 先端医療技術研究所
著者:
発行日: 2005-01-25
分野: 臨床医学:内科  >  腎臓
ISBN: 4925089382
電子書籍版: 2005-01-25 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

10,266 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,133 円(税込)

商品紹介

本書の前編「腎臓病の最新医療」から約4年。その後の腎臓病に関連するそれぞれの領域の変遷、進展、展望について記した新版。腎臓病に関する諸問題につき、わが国の現状も踏まえて詳しく各論で述べている。

目次

  • 先端医療シリーズ31 腎臓病 診断と治療の最前線

    ―目次―

    序文
    序章 腎臓病診療の課題と展望
    第1章 腎臓病の分子生物学
    第2章 原因遺伝子の解明と治療の新しいコンセプト
    第3章 難治性腎疾患治療の新たな展開
    第4章 糸球体疾患の診断と最新治療
    第5章 続発性腎疾患の診断と最新治療
    第6章 腎再生・腎移植
    第7章 透析・血液浄化療法の進歩
    第8章 腎不全患者の予後と合併症
    第9章 腎臓病患者における心血管
    第10章 RAASと腎炎
    第11章 診断&治療法の進歩
    第12章 腎臓疾患治療薬開発の最新情報
    第13章 各種製品の臨床評価
    技術資料編

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.5 掲載の参考文献
1) 日本透析医学会統計調査委員会:我が国の慢性透析療法の現況, 2004 (http://www.jsdt.or.jp/index.html)
7) 堺 秀人ほか:急速進行性腎炎症候群の診療指針.日腎誌 44:55-82, 2002
10) 武曾恵理:MPO-ANCA関連腎炎血管炎への経静脈敵ガンマグロブリン療法の展望.医学のあゆみ 266:157-159, 2003
17) National-Kidney-Foundation. Am J Kid Dis 39 (2) (Suppl 1):2002

第1章 腎臓病の分子生物学

P.12 掲載の参考文献
P.18 掲載の参考文献
P.22 掲載の参考文献
P.27 掲載の参考文献
P.32 掲載の参考文献
P.36 掲載の参考文献
P.40 掲載の参考文献
16) Hughey RP, Mueller GM, Bruns JB, et al:Maturation of the Epithelial Na+Channel Involves Proteolytic Processing of the α-and γ-Subunits. J Biol Chem 278:37073-37082, 2003
18) Tuyen DG, Kitamura K, Adachi M, et al:Inhibition of prostasin expression by TGF-βin renal epithelial cells. Kidney Int:2004 (in press)

第2章 原因遺伝子の解明と治療の新しいコンセプト

P.44 掲載の参考文献
P.48 掲載の参考文献
2) Wrong OM, Norden AGW, Feest TG:Dent:s disease:a familial renal tubular syndrome with hypercalciuria, tubular proteinuria, rickets, nephrocalcinosis and eventual renal failure. Q J Med 77:1086-1087, 1990
10) 0bermuler N, Grez N, Kriz W, et al:The swelling-activated chloride channel CIC-2, the chloride channel CIC-3, and CIC-5, a chloride channel mutated in kidney stone
15) Cebotaru V, et al:The CLC-5 knockout mouse model of Dent:s disease develop progressive renal failure. J Am Soc Nephrol 13:282A, 2002
disease, are expressed in distinct subpopulations of renal epithelial cells. J Clin Invest 101:635-642, 1988
P.54 掲載の参考文献
7) International Cystinuria Consortium:Non-type I cystinuria caused by mutations in SLC7A9, encoding a sub-unit (b0,+AT) of rBAT. Nat Genet 23:52-57, 1999
10) Mizoguchi K, Cha SH, Chairoungdua A, et al:Human cystinuria-related transporter:Localization and functional characterization. Kidney Int 59:1821-1833, 2002
16) Bisceglia L, Calonge MJ, Totaro A, et al:Localization, by linkage analysis, of the cystinuria type III gene to chromosome 19q13.1. Am J Hum Genet 60:611-616, 1997
20) Font MA, Feliubadalo L, Estivill X, et al:International Cystinuria Consortium. Functional analysis of mutations in SLC 7A9, and genotype-phenotype correlation in non-Type I cystinuria. Hum Mol Genet 10:305-316, 2001
P.58 掲載の参考文献
1) Paver WKA, Pauline GH:Hypertension and hyperpotassemia without renal disease in a young male. Medical Journal of Australia 2:305-306, 1964
6) Disse-Nicodeme S, Achard JM, Desitter I, et al:A new locus on chromosome 12p13.3 for pseudohypoaldo-steronism type H, an autosomal dominant form of hypertension. Am J Hum Genet 67:302-310, 2000

第3章 難治性腎疾患治療の新たな展開

P.64 掲載の参考文献
1) Tomino Y, Sakai H, Special Study Group (IgA nephropathy) on Progressive Glomerular Disease:Clinical guidelines for lmmunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 7:93-97, 2003
3) Tamura S, Ueki K, Ideura H, et al:Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clinical Nephrology 55:192-195, 2001
4) Rasche FM, Schwartz A, Keller F:Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clinical Nephrology 51:147-152, 1999
5) 服部謙志:IgA腎症に対する口蓋扁桃摘出術の治療効果と長期予後予測因子.日耳鼻 101:1412-1422, 1998
6) Hotta O, Miyazaki M, Furuta T, et al:Tonsillectomy and steroid pulse therapy significantly impact in patients with IgA nephropathy. Am J Kidney Disease 38:736-743, 2001
P.69 掲載の参考文献
1) 東條静夫:治療予後分科会まとめ.厚生省特定疾患ネフローゼ症候群調査研究班昭和49年度研究業績,p88-89, 1975
2) 土肥和紘:難治性ネフローゼの総括.厚生省特定疾患進行腎障害調査研究班平成10年度研究業績,p55-65, 1999
3) 堺 秀人,黒川 清,斉藤喬雄ほか:難治性ネフローゼ症候群 (成人例) の診療指針-平成13年度までの調査研究より. 日腎誌 44:751-761, 2002
5) Ponticelli C, Altieri P, Scolari F, et al:Arandomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9:444-450, 1998
7) Lieberman KV, Tej ani A:A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56-63, 1996
13) Rayner BL, Byrne MJ, van Zyl Smit R:Aprospective clinical trial comparing the treatment of idiopathic membra-nous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephro 146:219-224, 1996
15) 湯村和子:免疫抑制薬.長澤俊彦,二瓶 宏,湯村和子編:膠原病血管炎の腎障害,東京医学社,東京,p246-253, 2002
P.75 掲載の参考文献
1) 堺 秀人,黒川 清,小山哲夫ほか:急速進行性腎炎症候群の診療指針.急速進行性糸球体腎炎診療指針作成合同委員会:日本腎臓学会誌 44:55-82, 2002
2) Jennette JC:Rapidly progressive crescentic glomerulo-nephritis. Kidney Int 63:1164-1177, 2003
9) Nowack R, Gobel U, Klooker P, et al:Mycophenolate mofetil for maintenance therapy of Wegener:s granulo-matosis and microscopic polyangiitis:a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10:1965-1971, 1999
11) Levy JB, Pusey CD:Crescentic glomerulonephritis. In:Brady HR, Wilcox CS, editors. Therapy in Nephrology and Hypertension. 2nd ed. Saunders, London, p177-188, 2003
P.81 掲載の参考文献
2) Jennette JC, Falk RJ, et al:Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (2):187-192, 1994
3) 日本腎臓学会:, 急速進行性糸球体腎炎の治療指針.日本腎臓学会誌 44 (2):55-82, 2002
4) 橋本博史ほか:厚生省難治性血管炎に関する調査研究.平成 10年度研究報告書:213-229, 1999
5) 吉田雅治ほか:厚生省難治性血管炎に関する調査研究.平成 12年度総括研究報告:229-237, 2001
6) Ito-Ihara T, Ono T, Nogaki F, et al:Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephrol Dial Transplant (in press)
8) 古庄巻史ほか:川崎病におけるγ-グロブリンの大量点滴療法.基礎と臨床 17:659-672, 1983
10) Luqmani RA, Bacon PA, Moots RJ, et al:Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678, 1994
11) Muso E, Ito-Ihara T, Ono T, et al:Intravenous immuno. globulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Ingect Dis (In press)
17) Csernok E, Trabandt A, Muller A, et al:Cytokine profiles in Wegener:s granulomatosis:predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 42 (4):742-750, 1999
18) Kitching AR, Holdsworth SR, Tipping PG:Crescentic Glomerulonepritis a manifestation of a nephritogenic Thl response?Histol Histopathol 15 (3):993-1003, 2000
19) Uno K, Komiya T, Tsukamoto T, et al:Immunomodulatory effect of intravenous immunoglobulin (IVIg) therapy as reflected in the response of peripheral mononuclear cell fractions to Th1 inducible cytokines in a patient with MPO-ANCA-related glolnerulonephritis and vasculitis. Jpn J Ingect Dis (In press)
27) Dodd RY:Infectious risk of plasma donations:relationship to safety of intravenous immune globulins. Clin Exp Immunol 104 (Suppl 1):31-34, 1996
P.87 掲載の参考文献
1) 藤村吉博:血小板TTPとADAMTS13変異.高久史麿ほか編:Annual Review血液2003,中外医学社,東京, p 153-162, 2003
2) 松本雅則,八木秀男,藤村吉博:vWF-cleaving protease/ADAMTS13.臨床血液 44:159-167, 2003
4) Furlan M, Robles R, Lamie B:Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223-4234, 1996
5) Tsai HM:Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235-4244, 1996
6) Furlan M, Robles R, Solenthaler M, et al:Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097-3103, 1997
7) Rose BD, George JN:Diagnosis ofthrombotic thrombocytopenic purpura-hemolytic uremic syndrome. UpToDate 12.1, Wallesley, 2004
9) Niaudet P:Treatment of hemolytic uremic syndrome in children. UpToDate 12.1, Wallesley, 2004
10) http://www.naramed-u.ac.jp/-trans/flame.html
13) Calderwood SB:Clinical manifestations, diagnosis, and treatment of enterohemorrhagic Escherichia coli. UpToDate 12. 1, Wallesley, 2004
14) Rock GA, Shumak KH, Buskard NA, et al (Canadian Apheresis Study Group):Comparison of plasma ex-change with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393-397, 1991
P.91 掲載の参考文献
1) Schiffmann R, et al:lnfusion of α-galactosidase A reduces tissue globotriaosylceremide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365-370, 2000
2) Eng CM, et al:Safety and effiicacy of recombinant human of α-galactosidase A replacement therapy in Fabry:s dis-ease. N Engl J Med 345:9-16, 2001
5) 衛藤義勝ほか:ファブリー病患者に対するα-ガラクトシダーゼA補充療法の多施設臨床試験成績.小児科臨床 56:133-143, 2003
6) 衛藤義勝ほか:日本人ファブリー病患者における酵素補充療法:第三相オープン試験結果.小児科診療 66:1435-1444, 2003

第4章 糸球体疾患の診断と最新治療

P.96 掲載の参考文献
1) 吉澤信行,尾田高志:急性糸球体腎炎症候群.荒川正昭,長澤俊彦専門編集:最新内科学大系56,中山書店,東京, p3-30, 1995
5) 吉澤信行,山上和夫,尾田高志:急性糸球体腎炎.Year note 2003別冊SELECTED ARTICLES:739-752, 2003
11) Pancholi V, Fischetti VA:A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydroge-nase with multiple binding activity. J Exp Med 176 (2):415-426, 1992
P.103 掲載の参考文献
1) 厚生省特定疾患ネフローゼ症候群調査研究班 (上田 泰班長):昭和48年度研究業績,p7, 1974
3) Tarshish P, Tobin JN, Bernstein J, et al:Prognostic significance of the early course of minimal change nephritic syndrome:Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769-776, 1997
4) 松倉裕喜:微少変化型ネフローゼ症候群ステロイド治療の長期予後.日児腎誌 15 (Suppl 1):88, 2002
5) Iijima K, Hamahira K, Kobayashi A, et al:Immuno histochemical analysis of renin activity in chronic cyclosporine nephropathy in childhood nephrotic syndrome. J Am Soc Nephrol 11:2265-2271, 2000
6) Iijima K, Hamahira K, Tanaka R, et al:Riskfactor for cyclosporine-induced tabulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney lnt 61:1801-1805, 2003
P.107 掲載の参考文献
13) 今井裕一,小山雄太:膜性腎症.内科 89:1211-1214, 2002
14) 湯村和子,内田啓子,川嶋 朗ほか:ループス腎炎における免疫抑制薬ミゾリビンの血中濃度の評価.腎と透析 47:705-708, 1999
P.112 掲載の参考文献
5) Yata N, Ikeda M, Ishikura K, et al:Typical MPGN with few urinary abnormalities. Am J Kidney Dis 43:918-922, 2003
7) 0wen KR, Donohoe M, Ellard S, et al:Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome). Nephron Clin Pract 96:C35-38, 2004
9) Muhlfeld AS, Segerer S, Hudkins K, et al:Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int 65:1214-1223, 2004
10) Muhlfeld AS, Segerer S, Hudkins K, et al:Deletion of the fc-gamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol 163:1127-1136, 2003

第5章 続発性腎疾患の診断と最新治療

P.117 掲載の参考文献
1) Hahn AW, Resink TJ, Bernhardt J, et al:Stimulation of autocrine platelet-derived growth factor AA homodimer and transforming growth factor β in vascular smooth muscle cells. Biochem Biophys Res Commun 178:1451-1458, 1991
7) 鴨谷亮一:日本人の悪性高血圧.Modern Medicine 3:11-17, 1974
9) Jequier E:Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 987:979-988, 2002
12) European Society of Hypertension-European Society of Cardiology guidelines Committee:European Society of Hypertension-European Society of Cardiology guidelines for the management ofarterial hypertension. J Hypertens 21:1011-1053, 2003
14) 林晃一:腎保護を視点とした高血圧性臓器障害の予防治療.日本臨牀 62:135-141, 2004
P.122 掲載の参考文献
1) 愼野博史:糖尿病性腎症の臨床経過と病期分類.槇野博史編著:糖尿病性腎症-発症進展機序と治療 (第1版).診断と治療社,東京,p192-196, 1999
2) American Diabetes Association:Nephropathy in Diabetes. Diabetes Care 27 (Suppl 1):S79-83, 2004
3) Hayashi Y, Makino H, Ota Z:Serum and urinary concentrations of type W collagen and laminin as a marker of microangiopathy in diabetes. Diabet Med 9 (4):366-370, 1992
7) Kidney Disease Outocomes Quality Initiative (K/DOQI):K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (5 Suppl 1):S142-158, 2004
10) Chan JC, Wat NM, So WY, et al:Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes:an Asian perspective from the RENAAL study. Diabetes Care 27 (4):874-879, 2004
12) 赤井裕輝ほか:多角的強化療法による糖尿病性腎症の寛解. 伊藤克己,浅野 泰,遠藤 仁ほか編:Annual Review腎臓2002,中外医学社,東京,p250-257, 2002
14) Soulis-Liparota T, Cooper M, Papazoglou D, et al:Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40 (10):1328-1334, 1991
17) Miyata T, van Ypersele de Strihou C, Ueda Y, et al:Angiotensin II receptor antagonists and angiotensin-con-verting enzyme inhibitors lower in vitro the f () rmation of advanced glycation end products:biochemical mechanisms. J Am Soc Nephrol 13 (10):2478-2487, 2002
20) Vlassara H, Fuh H, Donnelly T, et al:Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
P.128 掲載の参考文献
3) Radhakrishnan J, Kunis CL, D:Agati V, et al:Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42:147, 1994
4) Austin HA, Vaugham EM, Boumpas DT, et al:Lupus membranous nephropathy:Controlled trial of prednisone, pulse cyclophosphamide and cyclosporine (abstract). JAm Soc Nephrol 11:A439, 2000
5) Dooley MA, Cosio FG, Nachman P, et al:Mycophenolate mofetil therapy in lupus nephritis. Clinical observations. J Am Soc Nephrol 10:833, 1999
6) 山田 明:降圧薬の多面的作用と腎保護効果-自己免疫疾患.腎と透析 57:24, 2004
10) Houssiau FA, Vasconcelos C, D:Cruz D, et al:Immuno-suppressive therapy in lupus nephritis:the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121, 2002
P.133 掲載の参考文献
1) 細谷龍男:痛風の腎障害の発症と進展に関する研究.慈恵医大誌 94:629-649, 1979
3) 日本泌尿器科学会日本Endourology ESWL学会日本尿路結石症学会編:尿路結石症の疫学,尿路結石症診療ガイドライン,東京,金原出版,p17-21, 2002
5) Yu TF, Gutman AB:Uric acid nephrolithiasis in gout:pre-disposing factors. Ann Intern Med 67:1133-1148, 1967
8) Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al:Mild Hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol 283:F1105-1110, 2002
9) Kang DH, Nakagawa T, Feng L, et al:Arole of uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888-2897, 2002
12) 高尿酸血症痛風の治療ガイドライン作成委員会編:腎障害合併例に対する尿酸降下薬の使用法,高尿酸血症痛風の治療ガイドライン,日本痛風核酸代謝学会,東京,p39-40, 2002

第6章 腎再生 腎移植

P.139 掲載の参考文献
1) Sainio K, Suvanto P, Davies J, et al:Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric epithelium. Development 124:4077-4087, 1997
2) Mendelsohn C, Batourina E, Fung S, et al:Stromal cells mediate retinoid-dependent functions essential for renal development. Development 126:1139-1148, 1999
5) Nishinakamura R, Matsumoto Y, Nakao K, et al:Murine homolog of SALLI is essential for ureteric bud invasion in kidney development. Development 128:3105-3115, 2001
14) Herzlinger D, Koseki C, Mikawa T, et al:Metanephric mesenchyme contains multipotent stem cells whose fate is restricted after induction. Development 114:565-572, 1992
P.144 掲載の参考文献
6) Tanaka H, Terada Y, Okado T, et al:Embryoid-body derived from Wnt4-transformed mouse Embryonic stem cells Differentiate into renal tubular-like cells (投稿中)
7) 長田道夫:ネフロン形成の分子制御.腎と透析51 No.5:569-577, 2001
P.149 掲載の参考文献
7) Imasawa T, et al:The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 12:1401-1409, 2001
P.153 掲載の参考文献
3) 0kano H, Ogawa Y, Nakamura M, et al:Transplantation ofneural stem cells into the spinal cord after injury. Semin Cell Dev Biol 14:191-198, 2003
4) Poulsom R, Forbes SJ, Hadivala-Dilke K, et al:Bone marrow contributes to renal paranchymal turnover and regeneration. J Pathol 195:229-235, 2002
6) 1masawa T, Utsunomiya Y, Kawamura T, et al:The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J Am Soc Nephrol 12:1401-1409, 2001
7) Nishinakamura R, Matsumoto Y, Nakao K, et al:Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development 128:3105-3115, 2001
8) 0sumi N, Inoue T:Gene transfer into cultured mammalian embryos by electroporation. Methods 24:35-42, 2001
P.159 掲載の参考文献
1) 日本臨床腎移植学会,日本移植学会:腎移植臨床登録集計報告 (2004)-1,2003年実施症例の集計報告.移植 39:171-176, 2004
2) 打田和治:タクロリムスを用いた腎移植成績,タクロリムス 5年長期生着フォーラム,Medical Tribune 12月25日号:2003
3) 両角国男,武田朝美,幅 俊人ほか:特集-臓器移植の病理,腎臓移植.移植 38:14-23, 2003
4) 日本臨床腎移植学会,日本移植学会:腎移植臨床登録集計報告 (2003)-3,2000年追跡調査報告.移植 39:57-64, 2004
5) 太田和夫,高橋公太,大場 忍ほか:ABO不適合移植の一例.腎と透析 27:117-120, 1989
10) Ter Meulen CG, van Riemsdijk I, Hene RJ, et al:Steroid-withdrawal at 3 days after renal transplantation with anti-IL2 receptor α therapy:A prospective, randomized, multicenter study. Am J Transplant 4:803-810, 2004
15) Ratner LE, Ciseck I. J, Moore RG, et al:Laparoscopic live donor nephrectomy. Transplantation 60:1047-1049, 1995
20) Cascalho M, Ogle BM, Platt JL:Xenotransplantation and the future of renal replacement. J Am Soc Nephrol 15:1106-1112, 2004
21) 高橋公太編:腎移植連絡協議会からの提言,献腎提供を増やすための取り組み-病院システムの確立を目指して-.日本医学館,東京,2002

第7章 透析・血液浄化療法の進歩

P.166 掲載の参考文献
1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況2003年12月31日現在.日本透析医学会,東京,2004
3) 山上征二:透析液安全基準策定報告.透析会誌 28:1487-1493, 1995
4) 2001,2004年度日本透析医学会学術集会コンセンサスカンファレンスにて決定され,現在論文作成中
5) 石森 勇,石田和寛,星野敏久ほか:内部濾過促進型血液透析器の溶質除去特性に及ぼす影響因子の検討.腎と透析 47別冊HDF療法:99:91-95, 1999
6) Buoncristiani U, Quintaliani G, Cozzari M, et al:Daily dialysis:long-term clinical-metabolic results. Kidney Int 33 (Suppl 24):S137-140, 1988
7) Buoncristiani U, Quintaliani G, et al:Dramatic improvement of clinical metabolic parameters and quality of life with daily dialysis. Int J Artif Organs 12:133-136, 1989
8) Buoncristiani U, Quintaliani G, Cozzari M, et al:Reversal of left ventricular hypertrophy in uremic patients by treatment with daily dialysis. Home Hemodialysis Int 1:32-36, 1997
11) 越川昭三,斎藤 明,秋澤忠男ほか:連日透析システム (AEK-10) による連日短時間血液透析の有効性と安全性の検討 (多施設共同試験).透析会誌 12:1709-1718, 2003
14) Tatsumi E, Takano H, Taenaka Y, et al:Developmemt of anovel integrated heart-lung assist device-A heparincoated, preprimed, all-in-one system. ASAIO Ab:A20, 1998
16) Saito A, Sugiura S, Takagi T, et al:Maintaining low concentration of plasma β 2-microglobulin with continuous slow hemofiltration. Nephrol Dial Transplant 10 (Suppl 3):52-56, 1995
17) Aebischer P, Ip TK, Miracoli L, et al:Renal epithelial cells grown on semipermeable processor. Trans Am Soc Artif Intern Organs 33:96-102, 1987
18) Aebischer P, Ip TK, Galletti PM:The bioartificial kidney:Progress toward an ultrafiltration device with renal epithelial cells processing. Life Support Sys 5:159-168, 1987
21) Weitzel WF, Fissell WH, Humes HD:Initial clinical experience with a human proximal tubule cell renal assist device (RAD). JAm Soc Nephrol 12 (Program and Abstracts issue):A279, 2001
22) Weitzel WF, Humes HD, Bartlett RH, et al:Early results with the bioartificial kidney in ICU patients with acute renal failure. J Am Soc Nephrol 13 (Program and Abstracts issue):A642, 2002
23) Humes HD, Weitzel WF, Swaniker FC, et al:Effect of renal cell therapy on the gene expression profiles of inflammation in patients with acute renal failure and multiorgan failure. J Am Soc Nephrol 13 (Program and abstracts Issue):A445, 2002
24) 0zgen N, Tarashima M, Aung T, et al:Evaluation of longterm transport ability of a bioartificial renal tubule device using LLC-PK1. Nephrol Dial Transplant 19:2198-2207, 2004
P.170 掲載の参考文献
1) Pacitti A, Tetta C, Mangiarotti G, et al:Beta-2-microglobulin serum profiles in different settings of mass transport and fluid pyrogen content. Kidney Int 41 (Suppl):S96-99, 1993
3) 鶴澤一行ほか:透析液清浄化の臨床効果.腎と透析51 別冊ハイパフォーマンスメンブレン:185-188, 2001
4) 第1回九州コンセンサスカンファレンス:"透析液を置換液として使用する際の水質管理基準"の解説.九州HDF検討会会誌 1:33-42, 1995
5) 山上征二:透析液安全基準策定報告「水質及びパイロジェンフィルター評価基準小委員会
6) 森井浩世,浅野 泰,内藤秀宗,竹澤真吾:AK100-Ultraのための透析液安全基準施設基準について.透析会誌31:1107-1109, 1998
7) 第46回日本透析医学会コンセンサスカンファレンス「新たな透析液安全基準の設定.透析会誌 34 (Suppl):637-638, 2001
8) 第49回日本透析医学会コンセンサスカンファレンス「血液浄化器の新分類~内部濾過と透析液水質による再評価.透析会誌 (in press)
9) 土田健司ほか:グラム陽性菌菌体成分による透析液汚染とその生物活性-慢性腎不全患者単球cytokine産生に関するET とPGの相乗効果.腎と透析38 別冊ハイパフォーマンスメンブレン:8-15, 1995
P.173 掲載の参考文献
3) Rindi P, Pilone, N, Ricco, V, et al:Clinical experience with a new hemodiafiltration (HDF) system. ASAIO Transactions 34:765-768, 1988
6) 木村 弘,芝本 隆,高橋雅彦ほか:中空糸有効長と中空糸充填率は低分子蛋白の除去能に作用するか.日本透析医学会雑誌 36:173-178, 2003
7) 庭山ゆう子,廣瀬 稔,渡辺 敏ほか:膨潤糸を用いた内部濾過促進型ダイアライザの性能.医工学治療 15:3-9, 2003
8) 石森 勇,峰島三千男,佐藤雄一ほか:超音波ドップラーによるダイアライザ内部濾過現象の検証.医工学治療 13:187-190, 2001
P.178 掲載の参考文献
1) Cooker LA, Holmes CJ, Hoff CM:Biocompartibility of icodextrin. Kidney Int 62 (Suppl 81):S34-45, 2003
2) Williams JD, Craig KJ, Topley N, et al:Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephro113 (2):470-479, 2002
7) Ota K, Akiba T, Nakao T, et al:Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5%icodextrin solution in Japanese patients. Perit Dial Int 23 (4):356-361, 2003
10) Johnson DW, Arndt M, O'shea A, et al:Icodextrin as salvage therapy in peritoneal dialysis patients with refrac-tory fluid overload. BMC Nephrol 2:2, 2001
14) Martin J, Sansone G, Cirugeda A, et al:Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis. Adv Perit Dial 19:191-194, 2003
15) Parikova A, Zweers MM, Struijk DG, et al:Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 19:186-190, 2003
P.184 掲載の参考文献
4) Moncrief JW, Popovich RP, Dasgupta M, et al:Reduction in peritonitis incidence in continuous ambulatory peritoneal dialysis with a new catheter and implantation technique. Perit Dial Int 13:S329-331, 1993
5) Moncrief JW, Popovich RP, Seare W, et al:Peritoneal dialysis access technology:The Austin Diagnostic Clinic experience. Perit Dial Int 16:S327-329. 1996
6) Han DC, Cha HK, So IN, et al:Subcutaneously implanted catheters reduce the incidence of peritonitis:during CAPD by eliminating infection by periluminal route. Adv Perit Dial 8:298-301, 1992
8) de Alvaro F, Selgas R, Bajo MA, et al:Moncrief:s technique for peritoneal catheter placement:Experience of a CAPD unit. Adv Perit Dial 10:199-202, 1994
9) Page DE, Turpin C:Asimple and inexpensive method of subcutaneous implantation of catheter distal segment using a Tenckhoff curled catheter. Perit Dial Int 20:85-87, 2000
10) 石黒 望:CAPDカテーテルの留置時期.臨床透析 17:939-944, 2001
11) Twardowski ZJ, Nichols WK, Nolph KD, et al:Swanneck prestermal catheter for peritoneal dialysis. Adv Perit Dial 8:316-324, 1992
12) 窪田 実,石黒 望,濱田千江子ほか:バスタブカテーテル (presternal catheter) の成績.腎と透析 49:59-63, 2000
13) Kubota M, Kanazawa M, Takahashi Y, et al:Plantation of presternal catheter using Moncrief technique:Aiming fo rfewer catheter-related complications. Perit Dial Int 21:S184-187, 2001
14) 窪田 実,小柳伊知朗,井尾浩章ほか:腹膜透析の新しい導入法;"Moncrief and Popovichのカテーテル挿入法"を用いた段階的導入.日本透析医学会雑誌 35:1279-1285, 2002
P.189 掲載の参考文献
2) 福井次矢:EBM (Evidence-based Medicine) と医療の質. 日本内科学会雑誌 91:3415-3420, 2002
4) 篠田俊雄:血漿浄化療法血液吸着療法.透析療法合同専門委員会編:血液浄化療法ハンドブック (改訂第3版),協同医書出版,東京,p174-191, 2004
9) Schroeder JO, Schwab U, Zennet R, et al:TPE and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Preliminary results of the LPSG Trial. Arthrit Rheum 40:S326, 1997
P.194 掲載の参考文献
1) Davison AM:β 2-microglobulin and amyloidosis:who is at risk?Nephrol Dial Transplant 10 (Suppl 10):48-51, 1995
4) Yamaguchi I, Hasegawa K, Takahashi N, et al:Apolipo-protein E inhibits the depolymerization of β 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry 40:8499-8507, 2001
5) Yamamoto S, Yamaguchi I, Hasegawa K, et al:Glycosami-noglycans enhance the trifluoroethanol-induced extension of β 2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15:126-133, 2004
6) Yamaguchi I, Suda H, Tsuzuike N, et al:Glycosaminogly-can and proteoglycan inhibit the depolymerization of β 2-microglobulin amyloid fibrils in vitro. Kidney Int 64:1080-088, 2003
9) Kazama JJ, Maruyama H, Gejyo F:Reduction of circulating β 2-microglobulin level for the treatment of dialysis-related amyloidosis. Nephrol Dial Transplant 16 (Suppl 4):31-35, 2001
10) Abe T, Uchita K, Orita H, et al:Effect of β 2-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 64:1522-1528, 2003
11) 下条文武,天野 泉,中澤了一ほか:β2-ミクログロブリン吸着器リクセルS-15およびS-35の臨床検討.透析会誌 36:117-123, 2003
12) 下条文武,木村秀樹,川口良人:透析アミロイド症に対する少量ステロイド治療の現況-アンケート集計結果より-.透析会誌 31:73-78, 1998
13) 大森健太郎,青池郁夫,青柳春樹ほか:透析皮膚掻痒症の実態-新潟県内41施設2474名の調査報告-.透析会誌 34:1469-1477, 2001
14) 金澤 均,大堀弘明,越川 信ほか:掻痒症軽減に対する PMMA膜 (BG-U) の臨床評価-2年間の観察-.日本血液浄化技術研究会雑誌 11:51-54, 2003
15) 山田智子,菅谷博之,青池郁夫ほか:痒みを有する透析患者に存在する肥満細胞脱顆粒因子の分離と透析膜による除去. 腎と透析55 (別冊):167-171, 2003

第8章 腎不全患者の予後と合併症

P.198 掲載の参考文献
2) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況 (2001年12月31日現在).日本透析医学会, 2002
3) 井関邦敏:統計手法を用いた透析療法の評価と対策.腎不全治療マニュアル,南江堂,東京,p155-163, 2004
5) Young EW, Albert JM, Satayathum S, et al:Predictors and Consequences of Altered mineral Metabolism among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (in Press)
7) Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, et al:Association of elevated serum PO4, CaXPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephro112:2131-2138, 2001
8) Kimata N, Albert JM, Akiba T, et al:Association of Serum Calcium and Phosphorus with Cardiac Mortality in hemodialysis Patients:New results from the DOPPS. J Am Soc Nephrol 15:3A-4A, 2004
9) 平澤由平,鈴木正司,伊丹儀友ほか:血液透析患者の腎性貧血に対する遺伝子組換えヒトエリスロポエチン製剤 (rHuEPO) 治療における維持Ht値と生命予後に関する大規模調査 (rHuEPO特別調査).日本透析医学会雑誌 36 (7):1265-1272, 2003
P.200 掲載の参考文献
5) 福原俊一,鈴鴨よしみ:SF-36日本語版マニュアル (version 2. 0), (非特) 健康医療評価研究機構,東京,2004 http://www.SF-36.jp
6) 三浦靖彦,Joseph Green,福原俊-:KDQOL-SFTM version 1.3 日本語版マニュアル,健康医療評価機構,京都, 2004
7) Fukuhara S, Matsumura S, Bito S, et al:Association of self-reported mental-health status with overall use of health-care resources in Japan. Quality of Life Research 8 (7):626, 1999
P.205 掲載の参考文献
1) Q/DOQI clinical practice guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Kidney Disease Outcome Quality lnitiative. Am J Kidney Dis 42 (supple 3):S1-147, 2003
2) Kinugasa E, Koshikawa S:Effects of PB-94 (sevelamer hydrochrolide), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients-A Randomised, Open Label, Dose Titration Study of PB-94 versus Caltan(R) Tablet 500 (calcium carbonate)-. J Am Soc Nephrol 12:755A, 2001
4) D'Haese PC, et al:A multicenter study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 85 (Suppl):S73-78, 2003
6) Monier-Faugere MC, Geng Z, et al:22-oxacalcitriol suppresses sedondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55:821-832, 1999
8) 重松 隆:ビタミンD静注療法におけるcalcitriol と maxacalciol (22-oxacalcitriol:OCT) の差異の考慮.第13回腎とビタミンD研究会記録集,p103-105, 2002
11) Goodman WG, Hladik GA, Turner SA, et al:The calcimimetics agant AMGO73 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002
12) Block GA, Martin KJ, de Francisco ALM, et al:Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. N Eng J Med 350:1516-1525, 2004
13) Siizaki K, Hatamura I, Negi S, et al:Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induced apoptosis in uremia. Kidney lnt 64:992-1003, 2003
14) 富永芳博:外科的副甲状腺摘出術総論.黒川 清監修,深川雅史編集:新しい透析骨症,日本メディカルセンター, 東京,P214-223, 2003
P.208 掲載の参考文献
2) Iwaki S, Suzuki R, Nomura K, et al:Oral zinc supplementation reduces mean erythropoiein (EPO) dose in EPO required hemodialysis patients. J Am Soc Nephrol 12:357A (abstract), 2001
3) Casadeval N, Nataf J, Viron B, et al:Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Eng J Med 346:469-475, 2002
4) Chen C, Sytowski AJ:The erythropoietin receptor and signal cascade. in Erythropoietin:Molecular Biology and Clinical Use, ed. by Wolfgang Jelkmann:FP Graham Publishing Co, USA, p165-194, 2003
6) Kiby SL:Gene therapy for renal anemia in mice with poly-cystic kidney using an adenovirus vector encording the human erythropoietin gene. Kidney lnt 55:1234-1240, 1999
10) Lelkmann W:The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacoki-netics of the recombinant drugs rhEPO and NESP. Eur J Haematol 69:265-274, 2002
11) Bailon P, Pahlke W, Brandt M, et al:CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia:a new agent with an innovative mechanism of action. Poster presentation in World Congr Nephrol, 2003
12) Tare N, Pill J, Hosel W, et al:Preclinical phermacodynamics and pharmacokinetics of CERA (Continuous Erythropoiesis Receptor Activator):a new erythropoietic agent for anemia management in patients with kidney disease. Poster presentation in World Congr Nephrol, 2003
15) Dougherty F, Leypold JK, Cheung A, et al:No effect of hemodialysis or homofiltration on concentrations of CERA (Continuous Erythropoiesis Receptor Activator):in vitro study results. Poster presentation in Am Soc Nephrol, 2003
P.214 掲載の参考文献
3) NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease:update 2000. Am J Kidney Dis 37 (Suppl 1):S186-189, 2001
5) 日本透析医学会:2004年版慢性血液透析患者における腎性貧血治療のガイドライン.日本透析医学会誌 37, 5巻末:1-26, 2004
7) Iain CM:CREATE:new strategies for early anemia management in renal insufficiency. Nephrol Dial Transplant 18 (Supp12):ii3-6, 2003
8) Roithnger FX, Punzengruber C:The influence of ACE-inhibitor on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol 42:309-314, 1994
10) Efrati S, Zaidenstein R, Dishy V, et al:ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2003
11) Douglas SK, Gregory AN, Christina MG, et al:Longitudinal follow-up and outcomes Among a population with chronic kidney disease in a large managed care organization. Arch Intern Med l64:659-663, 2004
15) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3):S12-28, 2003
P.219 掲載の参考文献
2) Miyata T, Ueda Y, Shinzato T, et al:Accumulation of alubumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure:Renal implications in the pathophysiology of pentosidine. JAm Soc Nephrol 7:1198-1206, 1996
5) Miyata T, Ueda Y, Yamada Y, et al:Carbonyl stress in uremia:Accumulation of carbonyls accelerate the formation of pentosidine, an advanced glycation end product:carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
6) Miyata T, Kurokawa K, van Ypersele de Strihou C (Advanced glycation and lipoxidation end products):Role ofreactive carbonyl compounds generated during carbohydrate and lipid metabolism (review). J Am Soc Nephrol 11:1744-1752, 2000
12) Miyata T, van Ypersele de Strihou C, Ueda Y, et al:Angiotensine II receptor antagonist and angiotensine converting enzyme (ACE) inhibitor scavenge oxidative radicals and lower in vitro the formation of advanced glycation end products. J Am Soc Nephrol 13:2478-2487, 2002

第9章 腎臓病患者における心血管病

P.224 掲載の参考文献
1) StPeter WL, Schoolwerth AC, McGowan T, et al:Chronic kidney disease:Issues and establishing programs and clinics for improved patient outcomes, Am J Kidney Dis 41:903-924, 2003
8) Segura J, Campo C, Gil P, et al:Development of chronic kidney disease and cardiovascular prognosis in essential hypertension. J Am Soc Nephrol 15:1616-1622, 2004
15) Laradat MI, Molitoris BA:Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol 22:459-473, 2002
P.229 掲載の参考文献
1) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification and stratification. Am J Kidney Dis 39:S1-266, 2002
11) Wright JT, Bakris G, Greene T, et al:Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421-2431, 2002
13) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2000年版,日本高血圧学会,東京,2000
14) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
18) Imanishi M, Yoshioka K, Okumura M, et al:Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early disbetic nephropathy. Kidney Int 63 (Suppl):S198-200, 1997
20) The EUCLID study group:Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792, 1997
22) Heart Outcomes Prevention Evaluation Study lnvestigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
P.233 掲載の参考文献
3) Luscher TF, Lie JT, Stanson AW, et al:Arterial fibromus-cular dysplasia. Mayo Clin Proc 62 (10):931-952, 1987
4) Kaplan NM:in Clinical Hypertension, 8th ed, Williams &Wilkins, Baltimore, p381-403, 2002
13) 0ei HY, Geyskes GG, Mees EJ, et al:The significance of captopril renography in the diagnosis in renovascular hypertension. Contrib Nephro 156:95-103, 1987
22) Luscher TF, Lie JT, Stanson AW, et al:Arterial fibromuscular dysplasia. Mayo Clin Proc 62 (10):931-529, 1987
24) Novick A, Scoble J, Hamilton G (edited by Novick AC, Scoble J, Hamilton G):in Renal Vascular Disease HBJ College&School Division, London, p303-314, 1996
27) Losito A, Gaburri M, Errico R, et all Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 52 (6):339-343, 1999
29) Texter SC:Ischemic nephropathy:where are we now?J Am Soc Nephrol 15:1974-1982, 2004
30) Krijnen P, van Jaarsveld BC, Steyerberg EW, et al:A clinical prediction rule for renal artery stenosis. Ann Intern Med 129:705-711, 1998
42) Connolly JO, Higgins RM, Walters HL, et al:Presentation, clinical features and outcome in different patterns of atherosclerotic renovascular disease. Q J Med 87:413-421, 1994
P.238 掲載の参考文献
7) Vacher-Coponat H, Pache X, Dussol B, et al:Pulmonary-renal syndrome responding to corticosteroids:consider cholesterol embolization. Nephrol Dial Transplant 12:1977-1979, 1997

第10章 Renin Angiotensin Aldosteron System(RAAS)と腎炎

P.242 掲載の参考文献
16) Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, et al:Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161:430-439, 1998
P.248 掲載の参考文献
7) Schuttert JB, Liu MH, Gliem N, et al:Human renal fibroblasts derived from normal and fibrotic kidneys show differences in increase of extracellular matrix synthesis and cell proliferation upon angiotensin n exposure. Pflugers Arch 446:387-393, 2003
9) 0kada H, Inoue T, Kanno Y, et al:Interstitial fibroblastlike cells express renin-angiotensin system components in a fibrosing murine kidney. Am J Pathol 160:765-772, 2002
10) 0kada H, Watanabe Y, Inoue T, et al:Angiotensin II type lreceptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochem Biophys Res Commun 314:403-408, 2004
16) Cordonnier DJ, Pinel N, Barro C, et al:Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. JAm Soc Nephrol 10:1253-1263, 1999
18) Klahr S, Morrissey JJ:Comparative study of ACE inhibitors and angiotensin n receptor antagonists in interstitial scarring. Kidney Int (Suppl 63):S111-114, 1997
19) 0kada H, Watanabe Y, Kikuta T, et al:Bradykinin decreases plasminogen activator inhibitor-1 esxpression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme inhibition. J Am Soc Nephrol 15:2404-2413, 2004
P.254 掲載の参考文献
1) Hatakeyama H, Miyamori I, Fujita T, et al:Vascular al-dosterone. Biosynthesis and a link to angiotensin III-in-duced hypertrophy ofvascular smooth muscle cells. J Biol Chem 269:24316-24320, 1994
3) Gomez-Sanchez CE, Zhou MY, Cozza EN, et al:Aldosterone biosynthesis in the rat brain. Endocrinol 138:3369-3373, 1997
4) 武藤重明:アルドステロン作用のメディエーター.腎疾患-states of arts 2003-2004,浅野 泰,小山哲夫編:医歯薬出版,東京,p91-93, 2003
5) Losel RM, Feuring M, Falkenstein E, et al:Nongenomic effects of aldosterone:cellular aspects and clinical impli-cations. Steroids 67:493-498, 2002
7) Moellic CL, Ouvrard-Pascaud A, Capurro C, et al:Early nongenomic events in aldosterone action in renal collecting duct cells:PKCα activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol 15:1145-1160, 2004
9) Juknevicious I, Segal Y, Kren S, et al:Effect of aldosterone on renal transforming growth factori?. Am J Physiol renal Physiol 286:F1059-1062, 2004
17) 古松慶之,勝二達也,和田 晃ほか:RAASに対するTriple blockadeによる腎炎治療の可能性.日腎会誌 46:158, 2004
18) 木下卓哉,阿部克成,宮崎正信ほか:ヒト腎組織におけるアルドステロン合成酵素遺伝子 (CYP11B2) の発現について. 日腎会誌 46:258, 2004
P.258 掲載の参考文献
13) Yoshimura A, Inui K, Nemoto T, et al:Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesngial proliferative nephritis. J Am Soc Nephrol 9:2027-2039, 1998
15) Terada Y, Inoshita S, Nakashima O, et al:Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol 9:2027-2039, 1998

第11章 診断と治療法の進歩

P.264 掲載の参考文献
1) 澤村良勝,田島政晴ほか:腎臓の超音波計測.日超医論文集 89:183-184, 1981
2) Miltec D, Fuckar Z, Sustic A, et al:Sonographic measurement of absolute and relative renal length in adults. JClin Ultrasound 26:185, 1998
P.268 掲載の参考文献
1) 加藤司顯,東原英二:体腔鏡を始める人のために.臨床泌尿器科 57:19-26, 2003
2) 東原英二,田中良典,堀江重郎ほか:腹腔鏡下副腎摘除術. 日本泌尿器科学会雑誌 83:395-400, 1992
3) 吉井将人,平尾佳彦:マイクロ波手術器の使い方.臨床泌尿器科 55:857-863, 2001
4) 加藤司顯,堀江重郎,奴田原紀久雄ほか:マイクロターゼを用いた腹腔鏡下腎部分切除術. Journal of microwave surgery 21:123-127, 2003
5) 松田公志:腎動脈遮断による腹腔鏡下腎部分切除術.Urology View 1:50-55, 2003
P.273 掲載の参考文献
2) Masai M, Nakatsu H, Shiseki Y, et al:Treatment of stones on an outpatient basis by extracorponeal shock wave lithotripsy using a EDAP LT-01+. Jpn J Endourol ESWL 4:34-38, 1991
5) 戸辺豊総,伊藤晴夫:ESWLの最近の動向.垣添忠生監修:泌尿器科-診断と治療の最前線,先端医療技術研究所,東京, p255-264, 2000
6) 日本泌尿器科学会,日本Endourology ESWL学会,日本尿路結石症学会編:尿路結石症診療ガイドライン,金原出版,東京,2002
7) 金水英俊,野村博之,及川剛宏ほか:Sonolithσを用いた ESWLの臨床経験.泌紀要 45:601-604, 1999
10) Alexander L, Markus H, Daniela SL, et al:Urolitiasis in horseshoe kidneys:therapeutic management. Urology 47:182-186, 1996
12) Silver N, Kremer I, Gaston DD, et al:Severe sepsis following extracorporeal shockwave lithotripsy. J Urol 145:1045-1046, 1991
15) 園田孝夫:Endourology, ESWLによる結石治療の評価基準.日泌尿会誌 80:505-506, 1989
18) Rutz-Danielczak A, Pupek-Musialik D, Raszej:a-Wanic B:Effect of extracorporeal shock wave lithotripsy on renal function in patients with kidney stone disease. Nephron 79:162-166, 1998
19) 栃木真人:外来ESWL.臨泌 50:289-292, 1996
20) 加藤修爾,丹田 均:ESWLその適応拡大の歩み.吉田 修,東間 紘,村井 勝編:泌尿器科疾患の最新医療.先端医療技術研究所,東京,p126-129, 2003

第12章 腎臓疾患治療薬開発の最新情報

P.277 掲載の参考文献
1) 大島久二:副腎皮質ステロイド薬の免疫抑制分子作用機構. 炎症と免疫 9:8-15, 2001
6) Moldenhauer I, et al:Alteration of structural order of human erythrocyte ghost membrane by glucocorticoids and influence of the glucocorticoid receptor antagonist RU486. In J Tissue React 16:113-119, 1994
8) Sanden S, et al:Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol 27:1265-1270, 2000
10) Wada T, et al:A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 11:1534-1541, 2000
15) Yokoyama H, et al:Strategies for treatment of adult nephrotic syndrome by cyclosporin A (cyclosporine). Clin Exp Nephrol 3:S40-47, 1999
P.282 掲載の参考文献
1) 高橋公太:免疫抑制療法と新規免疫抑制薬.Annual Review腎臓2003,中外医学社,東京, p152-157, 2003
2) 大塚一幸:免疫抑制薬.新移植免疫学,中外医学社,東京, p113-139, 2000
5) 田辺一成,東間 紘,高橋公太ほか:わが国における新規腎移植患者に対するBasiliximab (シムレクト) の急性拒絶反応抑制効果および安全性の検討.移植 37:18-31, 2002
7) 齋藤和英,高橋公太:Basiliximab,腎と透析 55:581-586, 2003
12) 千葉健治:スフィンゴシン1リン酸レセプターアゴニストによる循環リンパ球の減少とその応用.臨床免疫 39:220-225, 2003
13) Tedesco-Silva H, Mourad G, Kahan BD, et al:FTY720, a novel immunomodulator:efficacy and safety results from the first phase 2A study in de novo renal transplanta-tion. Transplantation 77:1826-1833, 2004
14) 市田隆文:免疫抑制剤.医薬ジャーナル40S-1:164-167, 2004
P.285 掲載の参考文献
1) 中山謙二,伊藤貞嘉:高血圧性腎疾患の治療とフォローアップ.現代医療 36:401-405, 2003
2) Guidelines Committee:2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 21:1011-1053, 2003
4) Morgensen CE, Neldom S, Tikkanen I:Randomised controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes. BMJ 321:1440-1444, 2000
12) Cases A:Omapatrilat:clinical pharmacology. Drugs Today ( Barc) 36:817-828, 2000
13) Taal MW, Nenov VD, Wong W, et al:Vasopeptidase inhibition affords greater renoprotection than angiotensinconverting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059, 2001
P.291 掲載の参考文献
1) KAoyagi, et al:Role of active oxygen on methylguanidine synthesis in isolated rat hepato cytes. Kidney International 23 (Suppl 22):S229-233, 1987
2) Aoyagi K, Ohba S, Narit M, et al:Regulation of biosynthesis of guanidinosuccinic acid in isolated rat hepatocytes and in vivo. Kidney Int 24 (Supple 16):S224-228, 1983
3) 青柳一正,成田光陽:各種疾患のフリーラジカルと漢方薬腎疾患.奥田拓男,吉川俊一編:フリーラジカルと和漢薬, 国際遺書出版,東京,p147-158, 1990
7) Mazifari A, et al:Arachidonic acid metabolites mediate angiotensin n-induced NADHINADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxidants & Redox Signaling 1:167-179, 1999
9) Aoyagi K, et al:The role of protein kinase C in the increased generation in isolated rat hepatocytes of the hydroxyl radical by puromycin aminonucleoside. Free Radical Reseach (in press)
10) Aoyagi K, Narita M:Mechanism of abnormal active oxygen generation in tissue cells by puromycin aminonucleoside. Acta Medica Biologica 39 (Suppl):53-62. 1991
11) 青柳一正ほか:STZラットにおけるハイドロキシルラジカル産生増加とその経時変化:クレアトールとメチルグアニジンの尿中排泄量による検討.伊藤克己,玄番宗一編:腎とフリーラジカル5,東京医学社,p92-93, 2000
13) Vinik A, Tesfaye S, Zhang D, et al:LY333531 treatment improves diabetic neuropathy (DPN) with symptoms. Presented at 62nd Scientific Sessions of American Diabetes Association, San Francisco, 2002 (abstract#321)

第13章 各種製品の臨床評価

P.294 掲載の参考文献
1) Luqmani RA, Bacon PA, Moots RJ, et al:Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671-678, 1994
4) 柏木伸仁,朝倉昭子郎,井出達夫ほか:家兎の感作関節炎に対する顆粒球体外吸着療法の効果.炎症 14:313-322, 1994
5) 柏木伸仁,橘 武彦,足立正一:顆粒球除去療法の開発と臨床応用.炎症と免疫 7:371-377, 1999
P.299 掲載の参考文献
1) Shire Pharmaceutical Group plc:Press release, March 24, 2004
2) Shire Pharmaceutical Group plc:Press release, October 27, 2004
4) National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 (4) (Suppl 3):S62-84, 2003
6) Locatelli F, D:Amico M, Pontoriero G:Lanthanum Carbonate. IDrugs 6 (7):688-695, 2003
7) Damment SJP, Webster 1:Nephrol Dial Transplant 18:(Suppl 4):683, 2003
8) Damment SJP, Webster 1:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003
9) Pennick M, Damment SJP, Gill M:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003
10) Stewart AJ, Fiddler G, Webster I:Poster presented at the 9th Asian Pacific Congress of Nephrology, Pattaya, 16-20, February, 2003
11) Finn WF, Joy MS:Poster presented at the 9th Asian Pacific Congress of Nephrology, Pattaya, 16-20, February, 2003
12) Fiddler G, Taeubel J, Webster I, et al:Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin, 8-12, June, 2003
14) Hutchison AJ:Poster presented at the Annual Meeting of the American Society of Nephrology, Philadelphia, 1-4, November, 2002
15) Hutchison A, AI F Baaj (on behalf of the International Lanthanum Carbonate Study group):Poster presented at the National Kidney Foundation Clinical Meeting, Dallas, 2-6, April, 2003
16) Finn WF, Joy MS, Webster I:Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, 14-17, November, 2003
17) D:Haese PC, Spasovski GB, Sikole A, et al:Kidney Int 63 (Suppl 85):S73-78, 2003

技術資料編

P.305 掲載の参考文献
P.307 掲載の参考文献
2) 佐中 孜ほか:競合EHSA法による血漿ペントシジンの測定法の確立と慢性腎不全患者における血漿ペントシジン濃度.腎と透析 47:867-872, 1999
3) 佐中 孜ほか:慢性腎不全の早期診断マーカーとしてのペントシジン測定の有用性.腎と透析 56:777-783, 2004
4) 加藤陽二ほか:Quantification of AGE and oxidative Stress Biomarkers in Human Urine. 第 8回国際メイラード反応研究会, 2004
P.311 掲載の参考文献
1) 谷叙孝:デキストラン硫酸を使った吸着材の原理と性能.日アフェレシス会誌 19:86-91, 2000
3) Diamond JR, et al:Analogous pathobiologic mechanisms in glomerulosclerosis and athero-sclerosis. Kidney Int 39:S29-34, 1991
4) 酒井聡一ほか:血漿交換療法の現況と展望.腎と透析 22:795-803, 1987
5) 酒井聡一ほか:難治性ネフローゼ症候群に対する LDL吸着療法の臨床効果-多施設共同研究成績-.腎と透析 33:321-328, 1992
8) 横山啓太郎,酒井聡一:難治性ネフローゼ症候群の治療-アフェレーシス療法.腎と透析 40:115-120, 1996
9) Muso E, et al:Does LDL-apheresis in steroid resitant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257-264, 1994
10) 吉澤亜人ほか:ステロイド抵抗性ネフローゼ症候群に対するLDL-アフェレーシスの有用性に関する検討.日腎会誌 45:25-31, 2003
11) 内田俊也ほか:LDL吸着療法はFSGSに有効か. 腎と透析 40:607-611, 1996
13) 近本裕子ほか:難治性原発性FSGS例における LDL吸着療法によるステロイド感受性の改善に関する検討.Ther Res 21:2638-2639, 2000
14) Lieberman KV, et al:Aramdomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56-63, 1996
15) 岡田知也ほか:LDL吸着療法を契機にシクロスポリンが奏効したステロイド抵抗性微小変化型ネフローゼ症候群の一例.日腎会誌 38:46-51, 1996
17) 武曾恵理:難治性ネフローゼ症候群へのLDLアフェレシス療法-症例のまとめと新しい方向性について-.Ther Res 24:1237-1239, 2003
19) 斉藤喬雄:難治性ネフローゼ症候群.内科 94:91-95, 2004
20) Kojima S, et al:Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 15:185-190, 1992
22) 河内 裕,清水不二雄:ネフローゼ症候群の成因-タンパク尿発症機序についての最近の知見.内科 94:5-12, 2004
23) 服部元史ほか:尿沈渣ポドカリキシン陽性細胞からみた高脂血症による糸球体上皮細胞障害.腎と脂質研究会講演記録集 9:10-13, 1996
24) 堺 秀人ほか:難治性ネフローゼ症候群 (成人例) の診療指針-平成13年度までの調査研究より-.日腎会誌 44:751-761, 2002
25) 池田裕史ほか:LDL Apheresisが有効であった微小変化型ネフローゼ症候群の3例.Ther Res 24:1293-1296, 2003
27) 柴田哲雄ほか:急性腎不全を合併しLDLアフェレーシスにて寛解したIgA腎症によるネフローゼ症候群の1例.透析会誌 27:233-236, 1994
28) 中尾俊之ほか:糖尿病性腎症に対するLDLアフェレシス.日アフェレシス会誌 17:85-90, 1998
29) 田上哲夫ほか:糖尿病性腎症に対する長期LDL 吸着療法の試み.Ther Res 24:1290-1292, 2003
32) 渋谷正樹ほか:難治性ネフローゼ症候群を呈し, LDL吸着療法およびフェノフィブラートの併用が有効であったループス腎炎の1例.Ther Res 23:1364-1366, 2002
33) 斉藤喬雄ほか:リポ蛋白糸球体症 (LPG) におけるLDLアフェレーシス.透析会誌 37 (suppl 1):618, 1999
35) Yanagisawa T, et al:Massive proteinuria after renal transplantation treated with LDL-apheresis. Transplant Proc 28:1482-1483, 1996
38) 大石徹也ほか:免疫吸着療法を施行したループス腎炎の2例.腎と透析 36:349-354, 1994
40) Mistry-Burchardi N, et al:Apheresis in lupus nephritis. Ther Apher 5:161-170, 2001
P.315 掲載の参考文献
1) Desnick RJ, Ioannou YA, Eng CM:α-Galacto-sidase A deficiency:Fabry diseae.:Scriver CR, Beaudet AL, Sly WS, et al editors:The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill, New York, p3733-3774, 2001
5) Sweeley CC, Klionsly B:Fabry's disease. Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148, 1963
6) Kint JA:Fabry's disease. α-Galactosidase deficiency. Science 167:1268, 1970
9) Desnick RJ, Dean KJ, Grabowski G, et al:Enzyme therapy in Fabry disease:Differential in vivo plasma clearance metabolic effectiveness of plasma and splenic α-galacotsidase isozymes. Proc Natl Acad Sci USA 76:5326, 1979
10) Kornreich R, Desnick RJ, Bishop DF:Nucleotide sequence of human α-galactosidase A gene. Nucleic Acids Res 17:3301, 1989
11) 桜庭 均:XII. 治療法-2. ファブリー病の酵素補充療法.Annual Review 2004腎臓,231-236, 2004
14) Eng CM, Guffon N, Desnick RJ, et al:Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease. N Engl J Med 345 (1):9-16, 2001
16) 衛藤義勝,大橋十也,宇都宮保則ほか:日本人ファブリー病患者における酵素補充療法:第II相オープン試験の結果.小児科診療 66 (8):1435-1444, 2003
17) Schoenmakere GD, Chauveau D, Grunfeld JP:Enzyme replacement therapy in Anderson-Fabry's disease:beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33-35, 2003
20) Spinelli L, Pisani A, Sabbatini M, et al:Enzyme replacement therapy with aglasidase βimproves cardiac involvement in Fabry's disease. Clin Genet 66:158-165, 2004
21) Hilz MJ, Brys M, Marthol H, et al:Enzyme replacement therapy improves function of C-, A δ-, and A β-nerve fibers in Fabry neuropathy. Neurology 62:1066-1072, 2004
P.320 掲載の参考文献
1) 厚生省厚生科学研究シルバーサイエンス研究高齢者に投与最適な新規製剤及び新規包剤容器の作成研究, 1988
2) 安藤正樹,幸崎敏之,樋口文男ほか:ポリスチレンスルホン酸カルシウムを含有するゼリー状製剤に関する検討.薬剤学 60:261-270, 2000
3) 前田憲志,山崎親雄,天野 泉ほか:慢性腎不全に伴う高カリウム血症に対するSK-189 (アーガメイトゼリー) の臨床的検討.腎と透析 49:137-152, 2000
4) 丸山高史,久野 勉,高橋佳子ほか:維持透析患者に対する陽イオン交換樹脂製剤のアーガメイトゼリーと散剤のクロスオーバー試験.臨床透析 19:1643-1649, 2003
5) 高嶋孝次郎,水野賀夫,有田光一ほか:血液透析患者におけるアーガメイトゼリーおよびカリメートの比較検討.医療薬学 30:584-587, 2004
P.324 掲載の参考文献
P.328 掲載の参考文献
2) Shibazaki T, Sakai O, et al:Mizoribine Reduces Urinary Protein Excretion in Rats Given Puromycin Amino-nucleoside. Am J Nephrol 16:167, 1996
3) 佐藤則博,白岩和巳:単クローン抗体5-1-6腎炎ラットにおけるミゾリビンの尿中蛋白排泄抑制効果.細胞 33 (1):28, 2001
5) 越川昭三ほか:免疫抑制薬ミゾリビン (HE-69) のステロイド抵抗性ネフローゼ症候群に対する臨床評価-プラセボを対照とした二重盲検比較試験-.腎と透析 34 (4):631, 1993
6) Shibazaki T, Sakai O, et al:A randomized open-label comparative study of conventional therapy verus mizoribine on lay therapy inpatients with steroid-resistant nephrotic syndrome (post marketing surrey). Clin Exp Nephrol 8:117, 2004
7) 湯村和子ほか:ループス腎炎における免疫抑制剤ミゾリビンの血中濃度の評価.腎と透析 47 (5):705, 1999
P.331 掲載の参考文献
2) 太田和夫ほか:腎移植後の急性拒絶反応に対する muromonab CD3の治療効果.腎と透析 27:143-156, 1989
3) 伊藤克己ほか:小児腎移植後の急性拒絶反応に対するmuromonab CD3の治療効果.小児科臨床 42:1551-1560, 1989
P.337 掲載の参考文献
3) Jolly S, et al:Excessive weight gain during peritoneal dialysis. Int Artif Organs 24:197-202, 2001
4) Boeschoten EW, et al:Changes in weight and lipid concentration during CAPD treatment. Perit Dial Int 8:19-24, 1988
5) Lameire N, et al:Effects of longterm CAPD on carbohydrate and lipid metabolism. Clin Nephrol 30:S53-58, 1988
6) Liberek T, et al:Peritoneal Dialysis fluid inhibition of phagocyte function:effects of osmolarity and glucose concentration. J Am Soc Nephrol 3:1508-1515, 1993
8) Mistry CD, et al:Icodextrin in peritoneal dialysis:early development and clinical use. Perit Diallnt 14 (suppl 2):S13-21, 1994
9) 太田和夫ほか:本邦におけるイコデキストリン透析液の臨床成績:ブドウ糖透析液を対照薬とした二重盲検比較試験の結果.腎と透析 55:211-219, 2003
10) Ota K. et al:Peritoneal Ultrafiltration and Serum lcodextrin Concentration During Dialysis with 7.5% Icodextrin Solution in Japanese Patients. Perit Dial Int 23:356-361, 2003
12) Nakayama M, et al:Multicenter Survey on Hydration Status and Control of Bllod Pressure in Japanese CAPD patients. Perit Dial Int 22:411-441, 2002
P.340 掲載の参考文献
1) Kreutmann HT, et al:Complete Amino Acid Sequence of Human Parathyroid Hormone. Bio-chemistry 17:5723-5729, 1978
3) Lepage R, et al:A non (1-84) circulating para-thyroid hormone (PTH) ineteferes with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809, 1998
6) Goodman W, et al:Specific measurement of PTH (1-84) in Various Forms of Renal Osteodystrophy (ROD) Assessed by Bone Histomorphometry. J Am Soc Nephrol 14:SU-PO 706, 2003
P.347 掲載の参考文献
1) 佐々木正富:ダイアライザーに用いられる膜の特徴:再生セルロース (血液透析スタッフのためのハイパフォーマンスメンブレン).東京医学社, 東京,p11-17,1990
2) 佐々木正富:一般的な再生セルロース膜とビタミンE改質セルロース (新しいハイパフォーマンスメンブレン),東京医学社,東京,p13-27,1998
3) Sasaki M, Takahashi A, Ito H, et al:Developmemt of Blood-compatible Cellulose Membranes for Hemodialysis:Cellulose structure and functional aspect:457-472, 1989
4) 星野政陽,佐々木正富,北村 真ほか:濾液再生方法による新しい血液浄化システムの開発.人工臓器 26 (1):147-152, 1997
5) 鈴木 大,飛田美穂,佐々木正富ほか:濾液再生方法による血液浄化システムの開発及び臨床評価.人工臓器 26 (1):153-156, 1997
6) 森田浩智,佐々木正富,斉藤 明:再生セルロースハイパーフォーマンスメンブランの大孔径化. 人工臓器 18 (3):1137-1140, 1989
7) 猿橋 誠,細矢範行,佐々木正富:再生セルロースハイパーフォーマンスメンブランの膜物性評価.人工臓器 24 (3):1015-1020, 1992
8) 森田浩智,谷利樹,佐々木正富:ノンスライスヘッターによる抗血栓性に優れたダイアライザーの開発.人工臓器 21 (3):1011-1014, 1992
9) 細矢範行,佐々木正富,竹沢真吾ほか:in vitro 実験によるplug透析器とpost dilution HDFの性能評価.医工学治療 10 (1):59-61, 1996
10) 細矢範行,佐々木正富,竹沢真吾:大量液置換可能な透析器の性能評価 (Plug透析器).人工臓器 25 (1):107-112, 1996
11) 細矢範行,佐々木正富,竹沢真吾:大量液置換可能な透析器の開発.腎と透析 (別冊):94-96, 1995
14) Tarhg D, Sung Y, Wei Y, et al:Effect of Vitamin E-bonded membrane on the 8-hydroxy 2-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney International 58:790-799, 2000
15) Bonnefont-Rousselot D, et al:Blood oxidative stress and lipoprotein oxidizability in haemodialysis patients:effect of the useof a vitamin E-coated dialysis membrane. Nephrology Dialysis Transplantation 15:2020-2028, 2000
16) Tanimu D, Giles C, Pagayon Ym, et al:The Effect of Vitamin E-Modified Dialysers on Acute Intra-dialytic Symptoms:a Comparative Crossover Study. Saudi Journal of Kidney Diseases and Transplantation 11 (4):559-562, 2000
17) Shimazu T, et al:Effect of Vitamin E-Modified Regenerative Cellulose Membrane on Neutrophil Superoxide Anion Radical Production and Lipid Peroxidation. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:251-260, 1999
20) 猿橋 誠,森田浩智,佐々木正富ほか:表面改質セルロース膜の開発とその生体適合性評価.人工臓器 21 (3):1025-1030, 1992
22) 江本秀斗,佐々木正富:ビタミンE固定化ダイアライザーの脂質:に及ぼす影響 (H).Vitamembrane:16-18, 2001
25) 猿橋 誠,渡辺秀樹,佐々木正富:ビタミンE改質セルロース膜の生体適合性評価.人工臓器 24 (3):631-636, 1995
26) 猿橋 誠,佐々木正富ほか:ビタミンE固定化ダイアライザーCL-EEの抗酸化作用に関する基礎検討.人工臓器 29 (1):161-165, 2000
27) 佐々木正富,猿橋誠:ビタミンE固定化ダイアライザー,CL-EEの抗酸化作用に関する基礎的検討,Vitamembrane:22-29, 2001
28) Takagi T, Momoi T, Ono M, et al:Biocompatibility of modified regenerated cellose membrane (CL-E). Kidney Dial High perform mem:9436:128-131, 1994
29) Ono M, Takagi T, Saito A:Clinical evaluation of dialyzer CL-12E. Jpn J Clin Dial 10 (10):1585-1591, 1994
31) Miroslav M, Katarina D, 01iver R, et al:A modified dialyzer with vitamin E and antioxidant defense parameters. Kidney lnternational 59 (Suppl 78):144-147, 2001
35) Inal M, Kanbak G, Sunal E, et al:Antioxidant Status and Lipid Peroxidation In Hemodialysis Patients Undergoing Erythropoietin and Erythropoietin-Vitamin E Combined Therapy. Free Rad Res 31:211-216, 1999
36) Taccone-Gallucci M, et al:Chronic Haemolysis and Erythrocyte Survival in Haemodialysis Patients Treated with Vitamin E-Modified Dialysis Filters. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:44-48, 1999
39) 0detti P, et al:Effect of a New Vitamin E-Coated Membrane on Glycoxidation during Hemodialysis. Vitamin E-Bonded Membrane. A Further Step in Dialysis Optimization. Contrib Nephrol. Basel, Karger 127:192-199, 1999
41) Mine M, Yukawa S, Yamada Y, et al:Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney International 56 (Suppl 71):S126-129, 1999
P.354 掲載の参考文献
7) 永野伸郎,福島 直:慢性腎不全患者の高リン血症に対する新規リン結合性ポリマー (塩酸セベラマー) の薬理作用ならびに臨床試験成績.日薬理誌 122:443-453, 2003
8) 永野伸郎,小花幸子,宮田そのえほか:新規リン吸着剤sevelamer hydrochlorideの血中コレステロール低下作用機序.透析会誌 36:47-54, 2003
14) 草野健一郎,勝俣京子,平田道則ほか:腎不全ラットの高リン血症に対する塩酸セベラマーの治療効果.薬理と治療 31:203-207, 2003
15) 永野伸郎,宮田そのえ,阿部めぐみほか:正常および腎不全ラットにおけるsevelamer hydro-chloride投与後の血清リンおよび副甲状腺ホルモン値の時間変化-時間制限給餌下での検討-.透析会誌 37:1423-1429, 2004
18) 三輪谷博史,内野盛恵,秋澤忠男ほか:リン結合剤PB-94 (Sevelamer Hydrochloride) の臨床第 I相試験-単回投与試験-.臨床医薬 19:547-555, 2003
19) 三輪谷博史,秋澤忠男:リン結合剤PB-94 (Sevelamer Hydrochloride) の臨床第I相試験-反復投与試験-.臨床医薬 19:557-567, 2003
20) 栗原 怜,鈴木正司,二瓶 宏ほか:透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-第II相用量設定試験-.腎と透析55:221-238, 2003
21) 鈴木正司,栗原 怜,大薗英一ほか:血液透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-沈降炭酸カルシウム製剤 (カルタン(R)錠500) を対照とした比較臨床試験-.腎と透析55:383-400, 2003
22) 大森浩之,鈴木正司,栗原 怜ほか:血液透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-長期投与試験-.腎と透析 55:513-531, 2003
23) 平松 信,東海林隆男,新倉一彦ほか:腹膜透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-第III相一般臨床試験-.腎と透析 55:653-663, 2003
24) Collins AJ, St Peter WL, Dalleska FW, et al:Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 54:334-341, 2000
26) De Smet R, Thermote F, Lameire N, et al:Sevelamer hydrochloride (Renagel ?) adsorbs the uremic compound indoxyl sulfate. ERA-EDTA XLI Congress Abstract Book, p104-105, 2004
P.358 掲載の参考文献
1) 川口良人,高久史麿,前田貞亮ほか:腎性貧血患者に対するRecombinant Human Erythropoietin (KRN5702) の長期投与による臨床的有用性の検討.臨床医薬 4:2075. 2100, 1988
4) Wu SC, Lin SL, Jeng FR:Influence of erythro-poietin treatment on gonadotropic hormone levels and sexual function in male uremic patients, Scand J Urol Nephrol 35:136-140, 2001
7) Xia H, Ebben J, Ma JZ, et al:Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
9) Macdougall IC:Novel erythropoiesis stimulating protein. Semin Nephrol 20:375-381, 2000
11) Akahori H, Tawara T, Ida M, et al:The effect of novel erythropoiesis stimulating Protein (NESP) on anemia induced by renal failure in rats. Exp Hematol 26:766, 1998
12) Macdougall IC, Gray SJ, Elston O, et al:Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395, 1999
16) http://wwwext.amgen.com/clinicians/prca./html
P.362 掲載の参考文献
2) Nemeth EF, Heaton WH, Miller M, et al:Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCI. J Pharmacol Exp Ther 308:627-635, 2004
4) Wada M, Furuya Y, Kobayashi N:The calcimimetic compound AMG073 (cinacalcet HCI) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol 14:48A, 2003
5) Wada M, Kawata T, Furuya Y:The calcimimetic compound KRN1493 suppresses parathyroid hyperplasia in rats with chronic renal in-sufficiency. J Bone Miner Res 17 (suppl 1):S212, 2002
7) Block GA, Martin KJ, Francisco ALM, et al:Cinacalcet for secondary hyperparathyroidism in patients receiving Hemodialysis. New Engl JMed 350:1516-1525, 2004
8) Torres PU:Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19 (suppl 5):v27-33, 2004
9) Cunningham J, Chertow G, Goodman W, et al:The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalization, and mortality in dialysis subjects with secondary hyperpar-athyroidism (HPT). XLI Congress Abstract Book, Eur Dialysis Transplant Assoc, p219, 2004
11) National Kidney Foundation:K/DOQI Clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3):S1-202, 2003

最近チェックした商品履歴

Loading...